Nuvation Bio Inc. (NUVB): Long-Term Debt

Annual figures by period end, from SEC filings.

$47.21M

As of 2025-12-31

$242.62M

As of 2026-06-30

Period ended	Long-Term Debt	Change YoY	Source filing
2025-12-31	$47.21M	n/a	2026-03-02, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Long-Term Debt	Change YoY
Nuvation Bio Inc. (NUVB)	2025-12-31	$47.21M	n/a
Fortress Biotech, Inc. (FBIO)	2025-12-31	$52.42M	-9.6%
Journey Medical Corp (DERM)	2025-12-31	$25.28M	+1.6%
Kura Oncology, Inc. (KURA)	2025-12-31	$9.70M	+1.9%
Eton Pharmaceuticals, Inc. (ETON)	2024-12-31	$29.81M	n/a
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	$96.37M	n/a
Standard Biotools Inc. (LAB)	2024-12-31	$299.0K	-99.5%
Cytokinetics Inc (CYTK)	2024-12-31	$619.52M	-3.1%
Aquestive Therapeutics, Inc. (AQST)	2025-12-31	$45.00M	0.0%

Compare NUVB, FBIO, DERM, KURA side by side · Screen every company in Pharmaceutical Preparations ↗